Korean J Pathol.
2013 Apr;47(2):100-106.
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
- Affiliations
-
- 1Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
- 2Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
- 3Department of Pathology, Inha University School of Medicine, Incheon, Korea.
- 4Department of Pathology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
- 5Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.
- 6Department of Pathology, National Cancer Center, Goyang, Korea.
- 7Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
- 8Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jangsejin@amc.seoul.kr
Abstract
- Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
- Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
- Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
- Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases
- Epidermal Growth Factor Receptor Expression of Non-small Cell Carcinoma and Its Relationship with Genomic Mutation
